Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Net Assets
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A net assets. Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has net assets worth CN¥5.67 Billion CNY (≈ $829.87 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.02 Billion ≈ $880.77 Million USD) and total liabilities (CN¥347.84 Million ≈ $50.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Wuhan Easy Diagnosis Biomedicine Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.67 Billion |
| % of Total Assets | 94.22% |
| Annual Growth Rate | 143.88% |
| 5-Year Change | 98.44% |
| 10-Year Change | 3130.37% |
| Growth Volatility | 1660.26 |
Net Assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
Net assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025. This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. See Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below shows the annual net assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025. For live market cap and overall valuation, see Wuhan Easy Diagnosis Biomedicine Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.66 Billion ≈ $827.62 Million |
-6.03% |
| 2024-12-31 | CN¥6.02 Billion ≈ $880.72 Million |
-4.35% |
| 2023-12-31 | CN¥6.29 Billion ≈ $920.73 Million |
-7.08% |
| 2022-12-31 | CN¥6.77 Billion ≈ $990.93 Million |
+137.60% |
| 2021-12-31 | CN¥2.85 Billion ≈ $417.06 Million |
+155.64% |
| 2020-12-31 | CN¥1.11 Billion ≈ $163.14 Million |
+81.10% |
| 2019-12-31 | CN¥615.62 Million ≈ $90.08 Million |
+3.89% |
| 2018-12-31 | CN¥592.59 Million ≈ $86.72 Million |
+143.93% |
| 2017-12-31 | CN¥242.93 Million ≈ $35.55 Million |
+38.76% |
| 2016-12-31 | CN¥175.08 Million ≈ $25.62 Million |
+51.73% |
| 2015-12-31 | CN¥115.39 Million ≈ $16.89 Million |
+132.69% |
| 2014-12-31 | CN¥49.59 Million ≈ $7.26 Million |
+264.74% |
| 2013-12-31 | CN¥13.60 Million ≈ $1.99 Million |
+855.19% |
| 2012-12-31 | CN¥1.42 Million ≈ $208.28K |
+6535.83% |
| 2011-12-31 | CN¥21.45K ≈ $3.14K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 410451033934.0% over the analyzed period, indicating profitable operations and earnings retention.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Net Assets Breakdown (December 2025)
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.10 Billion | 74.22% |
| Other Components | CN¥1.43 Billion | 25.78% |
| Total Equity | CN¥5.53 Billion | 100.00% |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spin Master Corp
TO:TOY
|
$494.20 Million |
|
Jiangsu Jinji Industrial Co Ltd
SHE:300798
|
$494.32 Million |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
$494.50 Million |
|
Zhejiang Jinghua Laser Technology Co Ltd Class A
SHG:603607
|
$494.50 Million |
|
Genbyte Technology Inc
SHE:003028
|
$494.03 Million |
|
Rainbow Tours SA
WAR:RBW
|
$493.81 Million |
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
$493.79 Million |
|
iQIYI Inc
F:IQ8
|
$493.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,826,392,063 to 5,528,437,166, a change of -297,954,897 (-5.1%).
- Net loss of 16,460,700 reduced equity.
- Dividend payments of 263,257,495 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-16.46 Million | -0.3% |
| Dividends Paid | CN¥263.26 Million | -4.76% |
| Other Changes | CN¥-18.24 Million | -0.33% |
| Total Change | CN¥- | -5.11% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥3557.05 | CN¥14.52 | x |
| 2012-12-31 | CN¥0.06 | CN¥14.52 | x |
| 2013-12-31 | CN¥0.23 | CN¥14.52 | x |
| 2014-12-31 | CN¥0.35 | CN¥14.52 | x |
| 2015-12-31 | CN¥0.76 | CN¥14.52 | x |
| 2016-12-31 | CN¥1.13 | CN¥14.52 | x |
| 2017-12-31 | CN¥1.55 | CN¥14.52 | x |
| 2018-12-31 | CN¥3.33 | CN¥14.52 | x |
| 2019-12-31 | CN¥2.93 | CN¥14.52 | x |
| 2020-12-31 | CN¥5.28 | CN¥14.52 | x |
| 2021-12-31 | CN¥13.18 | CN¥14.52 | x |
| 2022-12-31 | CN¥28.28 | CN¥14.52 | x |
| 2023-12-31 | CN¥26.54 | CN¥14.52 | x |
| 2024-12-31 | CN¥25.80 | CN¥14.52 | x |
| 2025-12-31 | CN¥23.78 | CN¥14.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Easy Diagnosis Biomedicine Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.21%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.08x
- Recent ROE (-0.30%) is below the historical average (109.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1180.66% | 20.79% | 0.62x | 91.26x | CN¥251.09K |
| 2012 | 98.49% | 19.76% | 1.52x | 3.27x | CN¥1.26 Million |
| 2013 | 53.86% | 28.22% | 1.09x | 1.75x | CN¥5.96 Million |
| 2014 | 43.44% | 37.26% | 0.95x | 1.23x | CN¥16.58 Million |
| 2015 | 30.85% | 37.34% | 0.71x | 1.16x | CN¥24.06 Million |
| 2016 | 34.09% | 42.34% | 0.72x | 1.13x | CN¥42.18 Million |
| 2017 | 27.22% | 39.66% | 0.64x | 1.07x | CN¥41.44 Million |
| 2018 | 10.44% | 34.82% | 0.29x | 1.05x | CN¥2.60 Million |
| 2019 | 6.81% | 22.92% | 0.28x | 1.05x | CN¥-19.45 Million |
| 2020 | 42.56% | 48.89% | 0.67x | 1.29x | CN¥358.75 Million |
| 2021 | 50.67% | 49.94% | 0.83x | 1.23x | CN¥1.13 Billion |
| 2022 | 64.75% | 39.97% | 1.15x | 1.41x | CN¥3.56 Billion |
| 2023 | 1.24% | 10.00% | 0.10x | 1.23x | CN¥-527.66 Million |
| 2024 | 1.28% | 21.29% | 0.05x | 1.13x | CN¥-508.12 Million |
| 2025 | -0.30% | -6.21% | 0.04x | 1.08x | CN¥-569.30 Million |
Industry Comparison
This section compares Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,078,907,511
- Average return on equity (ROE) among peers: 22.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | CN¥5.67 Billion | 1180.66% | 0.06x | $494.04 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $5.13 Billion | 16.57% | 0.36x | $384.61 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $4.24 Billion |
| Double Medical Technology Inc (002901) | $1.46 Billion | 25.48% | 0.14x | $2.56 Billion |
| Lepu Medical Tech Beijing (300003) | $511.23 Million | 39.39% | 0.19x | $3.40 Billion |
| INKON Life Technology Co Ltd (300143) | $81.55 Million | 14.06% | 1.01x | $817.03 Million |
| Edan Instruments Inc (300206) | $217.47 Million | 30.36% | 0.22x | $1.02 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $505.98 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $83.90 Million | 31.18% | 0.36x | $473.66 Million |
| Sinocare Inc (300298) | $1.24 Billion | 11.58% | 0.08x | $1.56 Billion |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more